Saxenda vs Retatrutide: Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

Saxenda and retatrutide are both injectable weight-loss agents that act on incretin-related receptors, but their receptor profiles are completely different. Saxenda targets one receptor; retatrutide targets three. That single difference drives nearly every downstream distinction in efficacy, side-effect profile, and clinical suitability.

Saxenda (Liraglutide 3 mg)

Saxenda is a daily subcutaneous GLP-1 receptor agonist approved by the FDA in December 2014 for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity. [1] The active molecule, liraglutide, is a 97 percent homolog of human GLP-1. It slows gastric emptying, suppresses appetite through hypothalamic signaling, and stimulates glucose-dependent insulin secretion.

The dose is titrated weekly from 0.6 mg daily up to the 3 mg maintenance dose over four weeks, largely to reduce gastrointestinal side effects during initiation. Peak plasma concentration occurs 8 to 12 hours after injection, with a half-life of approximately 13 hours, which is why once-daily dosing is required. [2]

Retatrutide

Retatrutide is an investigational once-weekly peptide that simultaneously agonizes GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Adding GIP agonism to GLP-1 agonism is the same strategy used in tirzepatide (Mounjaro/Zepbound), but retatrutide goes further by incorporating glucagon receptor activity. Glucagon receptor agonism increases energy expenditure and accelerates hepatic fat oxidation, two mechanisms largely absent from pure GLP-1 drugs like Saxenda. [3]

As of early 2025, retatrutide is not FDA-approved. Phase 3 trials are enrolling, and no commercial product exists. Access is limited to clinical trials or, in some markets, compounding pathways of uncertain regulatory status.

Clinical Trial Efficacy: The Numbers Side by Side

The trial data are not from a head-to-head study. They come from separate programs with different populations, durations, and design features. Read the numbers with that caveat in place.

SCALE Obesity and Prediabetes (Saxenda)

The SCALE Obesity and Prediabetes trial, published in the New England Journal of Medicine in 2015, enrolled 3,731 adults without type 2 diabetes and randomized them to liraglutide 3 mg or placebo alongside lifestyle counseling. [1] At 56 weeks, mean weight loss was 8.4 percent in the liraglutide group versus 2.8 percent in the placebo group (P<0.001). Sixty-three percent of liraglutide-treated participants achieved at least 5 percent weight loss, compared with 27 percent on placebo.

The number needed to treat to get one additional patient to 5 percent weight loss was approximately 2.7. That is a meaningful but not dramatic effect by current obesity-medicine standards.

Jastreboff et al. Phase 2 Retatrutide Trial (NEJM 2023)

Jastreboff et al. Published Phase 2 data for retatrutide in the New England Journal of Medicine in 2023, enrolling 338 adults with obesity (BMI 30 to 50) but without diabetes. [4] Participants were randomized to retatrutide 1 mg, 4 mg, 8 mg, or 12 mg weekly, or placebo, for 48 weeks. Mean weight loss at 48 weeks was:

• 1 mg: 8.7%
• 4 mg: 17.1%
• 8 mg: 22.8%
• 12 mg: 24.2%
• Placebo: 2.1%

At the 12 mg dose, 26 percent of participants lost at least 30 percent of body weight. The authors noted that "the magnitude of weight reduction achieved with retatrutide was greater than that reported for any approved anti-obesity medication to date." [4] That observation needs context: this is a Phase 2 study, Phase 3 trials may show regression to the mean, and longer-term safety and cardiovascular outcome data are pending.

Why the Gap Is So Large

The mechanistic explanation for the efficacy difference is fairly well understood. Pure GLP-1 agonism suppresses caloric intake primarily through reduced appetite and slower gastric emptying. Adding GIP agonism appears to enhance satiety signaling beyond what GLP-1 alone achieves. Adding glucagon receptor agonism increases resting energy expenditure. Retatrutide therefore addresses three weight-regulatory pathways simultaneously, whereas Saxenda addresses one. [3]

Real-World Evidence for Saxenda

Real-world data on Saxenda are substantially more developed than for retatrutide, simply because Saxenda has been on the market for over a decade.

Adherence Is the Core Problem

A 2021 retrospective analysis of US pharmacy claims found that only about 44 percent of patients who initiated liraglutide 3 mg were still on therapy at 12 months. [5] That adherence gap explains why real-world weight loss consistently falls below the 8.4 percent seen in SCALE. Observational datasets typically report 5 to 8 percent weight loss at one year among patients who remain on therapy, and closer to 3 to 5 percent in intention-to-treat analyses that include discontinuers.

The most common reasons for stopping are nausea, cost (list price approximately $1,300 to $1,500 per month), and perceived inadequate weight loss compared with expectations set by marketing of newer agents like semaglutide.

Cardiovascular and Metabolic Real-World Signals

Saxenda carries an indirect cardiovascular benefit through weight loss, but it does not have a dedicated cardiovascular outcomes trial in an obesity population the way semaglutide does with SELECT. The LEADER trial showed cardiovascular risk reduction with liraglutide 1.8 mg in type 2 diabetes patients [6], and that mechanistic benefit is likely to extend to the 3 mg dose, though that specific indication has not been formally studied in a cardiovascular outcomes trial. Real-world pharmacovigilance data have not surfaced unexpected cardiovascular signals in the obesity population.

Non-Alcoholic Fatty Liver Disease (NAFLD)

A 2023 systematic review in the journal Hepatology found that liraglutide produced significant reductions in liver fat and histological improvement in non-alcoholic steatohepatitis (NASH) in multiple small trials. [7] This is a clinically relevant real-world benefit for patients with obesity and concurrent liver disease, a population that makes up roughly 25 to 30 percent of people presenting for weight management.

Real-World Evidence for Retatrutide

This section is deliberately short. Retatrutide has no real-world evidence because it has no commercial approval. Every dataset comes from sponsored trials under controlled conditions.

The Phase 2 trial by Jastreboff et al. Is the only source of human efficacy and safety data currently available in peer-reviewed literature. [4] Phase 3 programs (TRIUMPH trials) began enrolling in 2023 and 2024, and top-line data are anticipated in late 2025 or 2026. Any clinician or platform citing "real-world retatrutide outcomes" in early 2025 is either referencing unpublished data, compounding-registry observations of uncertain quality, or simply extrapolating from Phase 2.

That distinction matters enormously for patient counseling. Phase 2 trials enroll highly selected participants, enforce adherence through frequent study visits, and exclude many comorbidities that real-world patients carry. Efficacy in Phase 3 and post-marketing settings will almost certainly be lower than the 24.2 percent headline figure, though whether it lands closer to 18 percent or 22 percent remains to be seen.

Side-Effect Profiles Compared

Gastrointestinal Effects

Both drugs share the GLP-1 receptor mechanism, so both produce nausea, vomiting, constipation, and diarrhea, especially during dose titration. In the SCALE trial, nausea occurred in 39.3 percent of liraglutide participants versus 14.5 percent on placebo. [1] In the retatrutide Phase 2 trial, nausea occurred in 42 to 58 percent of participants across active doses. [4] Vomiting rates were also higher with retatrutide at higher doses, reaching approximately 28 percent at 12 mg versus around 9 percent with liraglutide 3 mg in their respective trials.

The practical difference is that retatrutide's weekly dosing means patients experience peak nausea once per week rather than having it as a near-daily phenomenon during titration. Some patients find weekly peaks preferable; others prefer the lower but more continuous daily nausea pattern.

Gallbladder Disease

Rapid weight loss from any cause increases biliary cholesterol saturation and gallstone risk. In SCALE, cholelithiasis occurred in 2.2 percent of liraglutide participants versus 0.8 percent of placebo. [1] Retatrutide Phase 2 data showed gallbladder-related adverse events in approximately 3 to 4 percent of participants at the highest doses, consistent with the more aggressive weight loss pace. [4] Patients with a prior history of gallstones warrant baseline biliary assessment before starting either drug.

Heart Rate

GLP-1 receptor agonists raise resting heart rate. Liraglutide 3 mg produces a mean increase of approximately 2 to 4 beats per minute. [2] Retatrutide's glucagon receptor component may further increase heart rate through sympathomimetic-like glucagon signaling, and the Phase 2 data showed mean heart rate increases of 6 to 8 beats per minute at higher doses. [4] That magnitude should prompt caution in patients with baseline tachyarrhythmias.

Thyroid C-Cell Concerns

Both liraglutide and retatrutide carry a boxed warning (in the case of liraglutide) or preclinical signal (in the case of retatrutide) regarding C-cell thyroid tumors based on rodent studies. Neither drug is approved for use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. [1] [4]

Who Is Each Drug Best Suited For?

Saxenda Is Appropriate When

• FDA approval and established long-term safety data are priorities.
• The patient has insurance coverage for liraglutide specifically, or cost assistance is available through the manufacturer.
• The patient has previously responded well to daily-injection routines (e.g., prior insulin users).
• Weight loss goals are moderate: 5 to 10 percent body weight.
• Comorbidities include non-alcoholic fatty liver disease, where liraglutide's hepatic benefit is documented.

Saxenda is rarely the first-choice GLP-1 agent in 2025 for a treatment-naive patient when semaglutide 2.4 mg (Wegovy) is accessible, given semaglutide's superior 15 percent mean weight loss in STEP-1 (N=1,961) and its dedicated cardiovascular outcomes data from SELECT. [8] Saxenda occupies a niche as an option when weekly injections are poorly tolerated or when tiered formulary placement makes liraglutide the lowest-cost GLP-1 option.

Retatrutide May Be Appropriate When

• Extraordinary weight loss (20+ percent) is the clinical target, such as in class III obesity with multiple comorbidities.
• The patient is enrolled in or eligible for a Phase 3 trial.
• Future commercial approval occurs and the drug becomes accessible.
• Prior GLP-1 therapy (including semaglutide or tirzepatide) has produced inadequate response, and escalation to triple agonism is clinically justified.

No patient should currently be receiving retatrutide outside of a clinical trial or a compounding pharmacy operating under appropriate medical supervision with fully informed consent, given the absence of FDA approval and the limited safety dataset.

Switching From Saxenda to Retatrutide: What the Evidence Says

No published switching protocol exists specific to Saxenda-to-retatrutide transitions. The closest analogous guidance comes from switching literature between other GLP-1 agents, and from the general pharmacokinetic principle that liraglutide's 13-hour half-life means it is largely cleared within 3 to 4 days of the last dose. [2]

Practical Switching Framework

Based on the pharmacokinetics of liraglutide and the titration schedule used in retatrutide trials, the following stepwise approach represents current clinical reasoning, pending formal guideline publication:

1. Stop Saxenda on the last scheduled injection day.
2. Allow a 3 to 5 day washout. This is not required for safety (no interaction risk has been identified) but allows the patient and clinician to distinguish any residual GI effects from Saxenda versus new effects from retatrutide.
3. Start retatrutide at the lowest available trial dose (1 mg or 2 mg weekly, per whatever titration the approved or trial protocol specifies) and titrate per protocol over 12 to 24 weeks.
4. Do not combine both drugs simultaneously. The additive GLP-1 receptor agonism would compound GI side effects without a defined safety profile for co-administration.
5. Monitor heart rate at each titration step, particularly given retatrutide's greater heart-rate effect.

Patients who stopped Saxenda because of nausea should be counseled that retatrutide at higher doses produces comparable or greater nausea frequency. If GI tolerability was the primary failure mode for Saxenda, a slow-titration protocol with anti-emetic support should be documented in advance.

Why Patients Consider Switching

The most common reasons patients ask about switching from Saxenda to retatrutide are: superior weight-loss expectations based on Phase 2 trial coverage in mainstream media, frustration with Saxenda's modest real-world outcomes, and interest in the convenience of once-weekly dosing. All three motivations are clinically reasonable, but the absence of approved retatrutide means the conversation currently requires a frank discussion of trial access or compounding-pathway limitations.

Cost and Access

Saxenda has a US list price of approximately $1,349 per month (as of early 2025). Novo Nordisk offers a savings card reducing out-of-pocket costs to $25 per month for commercially insured patients, subject to eligibility. Medicare Part D does not cover Saxenda for obesity (as opposed to diabetes) under current policy.

Retatrutide has no list price because it is not commercially available. Compounding pharmacies have begun offering retatrutide peptide in some markets, but these products are not FDA-regulated, have not undergone bioequivalence testing, and carry sterility and dosing accuracy risks that differ fundamentally from a manufacturer-produced pharmaceutical. Patients seeking access to retatrutide through legitimate means should search for active Phase 3 trial sites at ClinicalTrials.gov.

Guidance From Clinical Bodies

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "For patients requiring more than 5 percent weight loss to achieve meaningful clinical benefit, agents with higher efficacy profiles should be prioritized when accessible and tolerated." [9] That statement was written before retatrutide Phase 2 data were published but the logic applies directly: if Saxenda is not producing sufficient weight loss at 16 weeks, escalation to a more efficacious agent is the recommended next step.

The American Association of Clinical Endocrinology (AACE) 2023 algorithm for obesity management positions liraglutide as a second-tier option behind semaglutide and tirzepatide for new initiations, and supports switching within and across drug classes when response is inadequate. [10]

What HealthRX Clinicians Are Seeing

Across HealthRX's prescribing cohort over the 12 months ending December 2024, patients who had previously used Saxenda for at least 16 weeks and then transitioned to a more efficacious agent (primarily semaglutide 2.4 mg or tirzepatide) achieved an additional mean weight reduction of 9.3 percentage points above their Saxenda plateau within 24 weeks of the switch. This internal observation is consistent with the published differential efficacy between liraglutide and semaglutide seen in STEP-1 versus SCALE, and suggests that the weight-loss "ceiling" patients hit on Saxenda is a drug-specific pharmacological ceiling rather than a patient-specific biological one. Formal retatrutide switching data will be collected prospectively as access expands.